Bitglass study finds that EMEA cloud adoption continues to outpace rest of the world
- EMEA cloud adoption has increased to 84 percent; 5 in 6 companies analy sed have deployed at least one cloud application
- Office 365 continues its domination over G Suite
- Financial services and healthcare see surge in cloud adoption rates
- Many organisations fail to deploy adequate cloud security
LONDON, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Bitglass, the Next-Gen CASB company, today released its second annual EMEA Cloud Adoption Report, which reveals rates of cloud adoption and deployment of security tools across Europe.
The findings show that EMEA cloud adoption continues to outpace the rest of the world, with 84 percent of EMEA organisations migrating to apps like Office 365, AWS, G Suite and Slack to leverage the productivity and cost benefits of the public cloud. The results found that EMEA cloud adoption rates have increased by 27 percent since the initial study in 2016.
Office 365 is the most widely adopted cloud application across EMEA. 65 percent of organisations now use this application – an increase of 51 percent compared to Bitglass’ 2016 study. Usage of AWS far exceeds the rate of AWS deployments globally. Worldwide only 8 percent use AWS while in EMEA that figure rises to 21.8 percent.
The report also finds that many EMEA organisations lack even the most basic security tools. Only 47 percent of organisations analysed had a single sign-on (SSO) tool in use, for example.
Rich Campagna, CMO at Bitglass said: “The results of this survey reinforce what we found in our 2016 study – organisations in EMEA are embracing cloud productivity apps but still lack the security tools necessary to protect data. In cloud-first environments, security must evolve to protect data on many more endpoints and in many more applications.”
- Office 365 adoption continues to grow. More than three times as many organisations now use Office 365 (65 percent) as use G Suite (19 percent). Office 365 adoption in EMEA has grown by over 50 percent in the last two years.
- Despite falling usage numbers overall, G Suite remains popular in France (30 percent adoption) and Spain (40 percent).
- AWS usage in EMEA exceeds the rate of AWS usage globally. 21.8 percent of EMEA organisations now use AWS, compared to just 8 percent worldwide.
- Government organisations lead the way from a vertical industry perspective with a 41.6 percent adoption rate. Utilities trailed with just 5.3 percent adoption.
- Regulated industries including finance and healthcare saw significant gains in cloud adoption rates. Within finance and healthcare, use of Office 365 has nearly doubled since 2016.
- Less than 50 percent of organisations have deployed even the most basic cloud security tool – SSO. Only 47 percent of organisations sampled had a SSO tool in use.
- SSO is most widely adopted in education (64 percent), biotech (54 percent) healthcare (53.7 percent) and finance (53.5 percent)
The Bitglass research team used company domains to identify the cloud apps deployed in each organisation, and whether security technologies such as single sign-on (SSO) are in use. The sample included 20,000 organisations in France, Germany, Netherlands, Italy, Spain and UK.
Bitglass, the Next-Gen CASB company, is based in Silicon Valley with offices worldwide. The company's cloud security solutions deliver zero-day, agentless, data and threat protection for any app, any device, anywhere. Bitglass is backed by Tier 1 investors and was founded in 2013 by a team of industry veterans with a proven track record of innovation and execution.
EMEA Media Contact for Bitglass
T: + 44 (0) 1252 717040
U.S. Media contact for Bitglass
T: (916) 710-0950
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Manufacturing Leadership Forum Will Highlight Enabling Industry 4.0 with Analytics25.9.2018 15:06 | Pressemelding
Upcoming Dates in Houston, Texas and Antwerp, Belgium PORTLAND, Ore., Sept. 25, 2018 (GLOBE NEWSWIRE) -- New dates for The Manufacturing Leadership Forum were announced today including Houston, Texas, US on October 9, 2018 at the Petroleum Club of Houston and on November 28, 2018 in Antwerp, Belgium at the Lindner WTC Hotel & City Lounge. The events are sponsored by Northwest Analytics, a leading provider of manufacturing intelligence and SPC software solutions for manufacturers. This premier manufacturing analytics educational event focuses on enabling Industry 4.0 programs with manufacturing analytics. The Forums will feature keynotes and case-study presentations from globally-recognized leaders in the application of manufacturing analytics. In its fourth year, The Manufacturing Leadership Forum will open with a keynote from analytics visionary, Dr. Lloyd Colegrove, Director of Data Services & Fundamental Problem Solving at The Dow Chemical Company. “The Manufacturing Leadership Foru
Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-10125.9.2018 14:00 | Pressemelding
Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer Phase 3 trial in treatment-naïve EGFR mutation-positive NSCLC patients targeted to commence in 2019 NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that positive preliminary safety and efficacy data from an ongoing Phase 1/2 clinical trial of CK-101 were presented yesterday in an oral presentation at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer in Toronto. The oral presentation included further details on, and updates from, the dataset announced previously. CK-101 is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being evaluated in advanced non
SpeeDx Begins Multisite U.S. Clinical Trials of ResistancePlus® MG Test25.9.2018 14:00 | Pressemelding
Test supports international guidelines for treating antibiotic resistant STI SYDNEY, Australia, Sept. 25, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. today announced the start of patient testing in their multisite U.S.-based clinical trials for ResistancePlus® MG (not available for sale in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma genitalium, also known as Mgen or MG, along with genetic markers linked to antibiotic resistance. In recent years, Mgen prevalence has increased globally and developed high rates of resistance to the common antibiotic treatment, azithromycin. "This test is an exciting new development that will increase the precision of patient care for patients impacted by Mycoplasma genitalium - a common sexually transmitted infection with limited treatment options,” notes Dr Maria Trent, Professor of Pediatrics and Public Health at Johns Hopkins Medicine. The SpeeDx ResistancePlus MG test is in use in laboratories acr
Novavax Initiates Phase 2 Clinical Trial of NanoFlu™ in Older Adults25.9.2018 13:00 | Pressemelding
First participants enrolled in Phase 2 clinical trial of quadrivalent NanoFlu formulations Top-line immunogenicity and safety data expected in the first quarter of 2019 Phase 2 results will support meeting with the U.S. Food and Drug Administration (FDA) and Phase 3 clinical trial design GAITHERSBURG, Md., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced the initiation of a Phase 2 dose and formulation confirmation clinical trial in older adults of NanoFlu, its nanoparticle seasonal influenza vaccine candidate. “Initiating this Phase 2 clinical trial of NanoFlu is an important milestone for Novavax,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “With top-line results expected in the first quarter of 2019, we plan to discuss these data with the FDA at an ‘End of Phase 2’ meeting and to agree on the appropriate Phase 3 clinical trial design to support licensure via accelerated approval. We continue to believe NanoFlu is a differen
CGAP Launches Photo and Video Contest Theme for 2018: Financial Inclusion in Africa25.9.2018 13:00 | Pressemelding
This year's CGAP contest is the first ever to accept short video entries WASHINGTON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- The Consultative Group to Assist the Poor’s (CGAP) 13th annual photo contest, launched today, is seeking striking images on financial inclusion in Africa. For the first time, short video submissions on Africa also will be accepted. Entries may be submitted through December 14, 2018. Each contestant may submit up to 20 photos or videos to compete for the Grand Prize worth US$ 2,000. This year CGAP is looking for original and compelling photographs and short videos that tell the story of how financial services empower poor people and communities in Africa. The region is a center for financial innovation -- home to M-Pesa, the mobile money service launched a decade ago now replicated across markets worldwide; host to vibrant FinTech and e-commerce companies; and to a growing off-grid sector that leverages digital finance. Together these innovators contribute toward lifti
Kick-starting health in the workplace25.9.2018 10:00 | Pressemelding
Over 800 organizations step, bike, swim and yoga their way to better health and wellbeing as the May 2018 Virgin Pulse Global Challenge Concludes ZURICH, Switzerland, Sept. 25, 2018 (GLOBE NEWSWIRE) -- On August 30th more than 270,000 people, across 144 countries, completed Virgin Pulse’s 100-day Global Challenge, moving them towards a more active, healthy and productive lifestyle. With this achievement, Virgin Pulse, an international leader in employee health and wellbeing, once again proves it’s helping to improve employee lives for good. The company’s Global Challenge event encourages exercise, mindfulness and healthy habits at work, leading to a happier culture and reduced costs to the organization. “Through increased awareness, education and motivation, employees master long-term, sustainable habits allowing them to arrive at work feeling more engaged, productive and equipped for peak performance,” says David Osborne, Chief Executive Officer of Virgin Pulse. “The follow-on effects
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom